Literature DB >> 4043657

Sterol and bile acid metabolism after short-term prednisolone treatment in patients with chronic active hepatitis.

Y Yamanishi, Y Nosaka, H Kawasaki, C Hirayama, S Ikawa.   

Abstract

Serum levels of squalene, cholesterol and bile acid were measured before and after short-term prednisolone administration in patients with chronic active hepatitis. Comparison with normal controls indicated that serum bile acid levels were increased significantly (p less than 0.01) in patients with chronic active hepatitis, but serum levels of squalene and cholesterol did not differ significantly between the two groups. After short-term prednisolone treatment, serum levels of squalene and cholesterol were increased significantly (p less than 0.01) as compared with the pretreatment level. On the other hand, while serum fasting bile acid levels were found to be increased significantly (p less than 0.01), serum clearance after oral administration of ursodeoxycholic acid improved significantly (p less than 0.05) after treatment. These results indicated that short-term prednisolone treatment increases sterol metabolism in the liver in patients with chronic active hepatitis, resulting from an increase in hepatic clearance of bile acids.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043657     DOI: 10.1007/bf02774711

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  21 in total

1.  Biliary excretion of bile acids and cholesterol in bile fistula rats; bile acids and steroids.

Authors:  S ERIKSSON
Journal:  Proc Soc Exp Biol Med       Date:  1957-03

2.  The stimulation of the cholesterol synthesis in rat liver by hydrocortisone.

Authors:  O Wiss; V Wiss
Journal:  Helv Chim Acta       Date:  1976-09-29       Impact factor: 2.164

3.  Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.

Authors:  G C Cook; R Mulligan; S Sherlock
Journal:  Q J Med       Date:  1971-04

4.  Steroid-induced lipemia. A complication of high-dosage corticosteroid therapy.

Authors:  J D Bagdade; D Porte; E L Bierman
Journal:  Arch Intern Med       Date:  1970-01

5.  Cholesterol 7 alpha-hydroxylase.

Authors:  N B Myant; K A Mitropoulos
Journal:  J Lipid Res       Date:  1977-03       Impact factor: 5.922

6.  The role of glucocorticoids in the regulation of the diurnal rhythm of hepatic beta-hydroxy-beta-methylglutaryl-coenzyme A reductase and cholesterol 7 alpha-hydroxylase.

Authors:  K A Mitropoulos; S Balasubramaniam
Journal:  Biochem J       Date:  1976-10-15       Impact factor: 3.857

Review 7.  Plasma lipids and lipoproteins in liver disease.

Authors:  N McIntyre
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

8.  Oral ursodeoxycholic acid tolerance test in patients with digestive disease.

Authors:  Y Yamanishi; Y Kishimoto; H Kawasaki; C Hirayama; S Ikawa
Journal:  Gastroenterol Jpn       Date:  1981

9.  Diagnostic significance of fasting serum bile acid in liver disease.

Authors:  C Hirayama; T Irisa; K Arimura; M Nakamura
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1976 Nov-Dec

10.  Plasma squalene: lipoprotein distribution and kinetic analysis.

Authors:  C D Saudek; B M Frier; G C Liu
Journal:  J Lipid Res       Date:  1978-09       Impact factor: 5.922

View more
  3 in total

Review 1.  Nuclear receptors as drug targets in cholestatic liver diseases.

Authors:  Emina Halilbasic; Anna Baghdasaryan; Michael Trauner
Journal:  Clin Liver Dis       Date:  2013-05       Impact factor: 6.126

Review 2.  Clinical application of transcriptional activators of bile salt transporters.

Authors:  Anna Baghdasaryan; Peter Chiba; Michael Trauner
Journal:  Mol Aspects Med       Date:  2013-12-12

3.  Regulation of Fgf15 expression in the intestine by glucocorticoid receptor.

Authors:  Kunzhi Jia; Danping Zhang; Qi Jia; Qing-Yu Zhang
Journal:  Mol Med Rep       Date:  2019-01-30       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.